Ameriprise
ASND icon

Ameriprise’s Ascendis Pharma A/S ASND Stock Holding History

Ameriprise’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.1M Buy
+411,500
New +$92.2M 0.02% 576

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise's ASND Position: Q1 2026 in Review

Ameriprise reduced its Ascendis Pharma A/S (ASND) stake by 13% in Q1 2026, selling an estimated $16.6M and leaving 476,466 shares worth $109M. The position accounts for 0.03% of the portfolio, ranked #527.

Ameriprise first reported a position in ASND in Q1 2019 and has held it in 29 quarters since. The position peaked at $117M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Ameriprise held 476,466 shares of Ascendis Pharma A/S worth $109M as of Q1 2026.
  • Ameriprise sold 74,011 Ascendis Pharma A/S shares in Q1 2026, an estimated $16.6M.
  • Ascendis Pharma A/S made up 0.03% of Ameriprise's portfolio in Q1 2026, its #527 holding.
  • Ameriprise first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 29 quarters since.
  • Ameriprise's Ascendis Pharma A/S position peaked at $117M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.